ImageneBio (IMA) Other Accumulated Expenses (2020 - 2025)
ImageneBio (IMA) posted Other Accumulated Expenses of $280000.0 for Q4 2025, down 92.0% sequentially from $3.5 million in Q3 2025, and up 191.67% YoY from $96000.0 in Q4 2024.
ImageneBio (IMA) Other Accumulated Expenses (2020 - 2025) Analysis & Trends
ImageneBio has reported Other Accumulated Expenses for 6 years, with the latest figure at $280000.0 in Q4 2025.
- Quarterly Other Accumulated Expenses rose 191.67% year-over-year to $280000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $280000.0 (up 191.67% YoY) and the FY2025 annual result came in at $280000.0, up 191.67% from the prior year.
- Other Accumulated Expenses eased to $280000.0 in Q4 2025 per IMA's latest filing, from $3.5 million in the prior quarter.
- Over five years, Other Accumulated Expenses peaked at $6.1 million in Q3 2023 and troughed at $96000.0 in Q4 2024.
- A 5-year average of $2.5 million and a median of $2.3 million in 2022 frame the typical range for Other Accumulated Expenses.
- The sharpest annual moves came in 2022 and 2024: Other Accumulated Expenses surged 203.95% in 2022, then tumbled 97.58% in 2024.
- Over 5 years, Other Accumulated Expenses stood at $2.5 million in 2021, then soared by 79.27% to $4.5 million in 2022, then declined by 11.16% to $4.0 million in 2023, then sank by 97.58% to $96000.0 in 2024, then surged by 191.67% to $280000.0 in 2025.
- According to Business Quant data, Other Accumulated Expenses over the past three periods registered $280000.0, $3.5 million, and $1.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | ImageneBio | 47.79 Mn | -87.56 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 280,000.00 |
| Sep 30, 2025 | 3.50 Mn |
| Jun 30, 2025 | 1.11 Mn |
| Mar 31, 2025 | 1.65 Mn |
| Dec 31, 2024 | 96,000.00 |
| Sep 30, 2024 | 1.21 Mn |
| Jun 30, 2024 | 843,000.00 |
| Mar 31, 2024 | 2.26 Mn |
| Dec 31, 2023 | 3.96 Mn |
| Sep 30, 2023 | 6.14 Mn |
| Jun 30, 2023 | 3.44 Mn |
| Mar 31, 2023 | 3.55 Mn |
| Dec 31, 2022 | 4.46 Mn |
| Sep 30, 2022 | 5.31 Mn |
| Jun 30, 2022 | 2.77 Mn |
| Mar 31, 2022 | 2.38 Mn |
| Dec 31, 2021 | 2.49 Mn |
| Sep 30, 2021 | 1.75 Mn |
| Jun 30, 2021 | 1.91 Mn |
| Mar 31, 2021 | 1.33 Mn |